2025年03月, 北海道大学, 北海道大学大学院保健科学院長賞　　　　　　　　　　　　　　　
櫻井知子

2025年03月, 北海道大学, 北海道大学大塚賞　　　　　　　　　　　　　　　
櫻井知子

2024年09月, 日本臨床検査医学会北海道支部, 学会賞　　　　　　　　　　　　　　　
食品由来成分KaempferolのHDLに対する抗酸化作用
櫻井知子

2024年08月, 日本臨床化学会, 学会賞奨励賞　　　　　　　　　　　　　　　
ケンペロールによるミトコンドリアへの作用
櫻井知子

酸化脂肪滴の形成予防効果及びカルジオリピンプロフィール改善効果を同時評価するcell-based modelの開発　　　　　　　　　　　　　　　
柴田 ゆず, 櫻井 俊宏, 櫻井 知子, 惠 淑萍
日本未病学会学術総会抄録集, 32回, jma32002, 00023, (一社)日本未病学会, 2025年11月
日本語

KaempferolのHDLへの抗酸化作用によるMASLD予防効果の期待　　　　　　　　　　　　　　　
櫻井 知子, 櫻井 俊宏, 笹 真穂, 益子 真明, 佐藤 美涼, 惠 淑萍
日本未病学会学術総会抄録集, 32回, jma32002, 00033, (一社)日本未病学会, 2025年11月
日本語

LDL酸化修飾による肝細胞でのコレステロール代謝応答の時間的変化　　　　　　　　　　　　　　　
金 洛伶, 櫻井 俊宏, 佐久間 姫乃, 櫻井 知子, 村上 奈々緒, 惠 淑萍
日本未病学会学術総会抄録集, 32回, jma32002, 00073, (一社)日本未病学会, 2025年11月
日本語

Increased phosphatidylcholine and its hydroperoxides in serum low-density lipoproteins from patients with non-alcoholic steatohepatitis
Nanao Murakami, Toshihiro Sakurai, Arisa Yamahata, Akiko Sakurai, Kazuhiro Nouso, Yuki Fujii, Hitoshi Chiba, Shu-Ping Hui
Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, 61, 5, 406, 409, SAGE Publications, 2024年06月19日
研究論文（学術雑誌）, Background

Non-alcoholic fatty liver disease is classified into simple steatosis (SS) and non-alcoholic steatohepatitis (NASH) according to histological findings from liver biopsies. Phosphatidylcholine (PC), the main component of phospholipids in serum lipoproteins, is easily oxidized to phosphatidylcholine hydroperoxide (PC-OOH). Although a lipid composition in the low-density lipoproteins (LDL) from patients with NASH could be abnormal, it remains unclear. Here, to better understand the characteristics of lipids in the LDL from NASH and SS, we compared the composition of PC and PC-OOH species in LDL particles (LDL-PC, LDL-PCOOH) from these patients, then clarified the association between these lipids and NASH severity.

Methods

The serum samples from patients with NASH (female, n = 9) and SS (female, n = 4; male, n = 2) were used for isolation of LDL. Total lipids were extracted from isolated LDL, and the species of PC and PC-OOH were measured using liquid chromatography-mass spectrometry/mass spectrometry.

Results

The sum of LDL-PC and the sum of LDL-PCOOH were significantly higher in NASH than in SS. Several LDL-PC (PC 32:0, 32:1, 32:2, 34:3, 36:2, sum of PC with saturated fatty acyl chains and sum of LDL-PC with polyunsaturated fatty acyl chains) and several LDL-PCOOH (34:2, 36:2, 36:3 and total) were increased significantly with increasing fibrosis score. In particular, a series of LDL-PCOOH were more reflective of the severity of fibrosis score.

Conclusions

LDL-PC and LDL-PCOOH species were strongly correlated with the fibrosis score in NASH, which suggests that abnormal LDL is involved in the development of liver fibrosis.

Kaempferol Improves Cardiolipin and ATP in Hepatic Cells: A Cellular Model Perspective in the Context of Metabolic Dysfunction-Associated Steatotic Liver Disease
Akiko Sakurai, Toshihiro Sakurai, Hsin-Jung Ho, Hitoshi Chiba, Shu-Ping Hui
Nutrients, 16, 4, 508, 508, MDPI AG, 2024年02月11日
研究論文（学術雑誌）, Targeting mitochondrial function is a promising approach to prevent metabolic dysfunction-associated steatotic liver disease (MASLD). Cardiolipin (CL) is a unique lipid comprising four fatty acyl chains localized in the mitochondrial inner membrane. CL is a crucial phospholipid in mitochondrial function, and MASLD exhibits CL-related anomalies. Kaempferol (KMP), a natural flavonoid, has hepatoprotective and mitochondrial function-improving effects; however, its influence on CL metabolism in fatty liver conditions is unknown. In this study, we investigated the effects of KMP on mitochondrial function, focusing on CL metabolism in a fatty liver cell model (linoleic-acid-loaded C3A cell). KMP promoted mitochondrial respiratory functions such as ATP production, basal respiration, and proton leak. KMP also increased the gene expression levels of CPT1A and PPARGC1A, which are involved in mitochondrial β-oxidation. Comprehensive quantification of CL species and related molecules via liquid chromatography/mass spectrometry showed that KMP increased not only total CL content but also CL72:8, which strongly favors ATP production. Furthermore, KMP improved the monolysocardiolipin (MLCL)/CL ratio, an indicator of mitochondrial function. Our results suggest that KMP promotes energy production in a fatty liver cell model, associated with improvement in mitochondrial CL profile, and can serve as a potential nutrition factor in preventing MASLD.

Identification of a β-Carboline Alkaloid from Chemoselectively Derived Vanilla Bean Extract and Its Prevention of Lipid Droplet Accumulation in Human Hepatocytes (HepG2)
Dya Fita Dibwe, Nire Takeishi, Saki Oba, Akiko Sakurai, Toshihiro Sakurai, Takayuki Tsukui, Hitoshi Chiba, Shu-Ping Hui
Molecules, 28, 24, 8024, 8024, MDPI AG, 2023年12月09日
研究論文（学術雑誌）, Targeting bioactive compounds to prevent lipid droplet accumulation in the liver, we explored an antioxidative extract from vanilla bean (Vainilla planifolia) after chemo-selective derivatization through heating and acid modification. The chemical analysis of vanilla bean extract through chemoselective derivatization resulted in the identification of sixteen compounds (34–50) using LC-MS/MS analysis. A β-carboline alkaloid with a piperidine C-ring and a vanillin moiety at C-1 (34) was identified by molecular networking and diagnostic fragmentation filtering approaches. β-carboline alkaloid 34 exhibited significant inhibitory activity of lipid droplet accumulation (LDAI) in oleic acid-loaded hepatocellular carcinoma HepG2 cells. The LDAI activity was associated with both activation of lipolysis and suppression of lipogenesis in the cells. The study indicates that crude plant extracts, following chemoselective derivatization, may contain bioactive compounds that could be beneficial in preventing hepatosteatosis and could serve as a source of lead compounds for drug development. This approach may be useful to investigate other mixtures of natural products and food resources.

Oxidized Low-Density Lipoproteins Trigger Hepatocellular Oxidative Stress with the Formation of Cholesteryl Ester Hydroperoxide-Enriched Lipid Droplets
Iku Sazaki, Toshihiro Sakurai, Arisa Yamahata, Sumire Mogi, Nao Inoue, Koutaro Ishida, Ami Kikkai, Hana Takeshita, Akiko Sakurai, Yuji Takahashi, Hitoshi Chiba, Shu-Ping Hui
International Journal of Molecular Sciences, 24, 5, 4281, 4281, MDPI AG, 2023年02月21日
研究論文（学術雑誌）, Oxidized low-density lipoproteins (oxLDLs) induce oxidative stress in the liver tissue, leading to hepatic steatosis, inflammation, and fibrosis. Precise information on the role of oxLDL in this process is needed to establish strategies for the prevention and management of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Here, we report the effects of native LDL (nLDL) and oxLDL on lipid metabolism, lipid droplet formation, and gene expression in a human liver-derived C3A cell line. The results showed that nLDL induced lipid droplets enriched with cholesteryl ester (CE) and promoted triglyceride hydrolysis and inhibited oxidative degeneration of CE in association with the altered expression of LIPE, FASN, SCD1, ATGL, and CAT genes. In contrast, oxLDL showed a striking increase in lipid droplets enriched with CE hydroperoxides (CE-OOH) in association with the altered expression of SREBP1, FASN, and DGAT1. Phosphatidylcholine (PC)-OOH/PC was increased in oxLDL-supplemented cells as compared with other groups, suggesting that oxidative stress increased hepatocellular damage. Thus, intracellular lipid droplets enriched with CE-OOH appear to play a crucial role in NAFLD and NASH, triggered by oxLDL. We propose oxLDL as a novel therapeutic target and candidate biomarker for NAFLD and NASH.

Composition of plasmalogens in serum lipoproteins from patients with non-alcoholic steatohepatitis and their susceptibility to oxidation
Akiko Ikuta, Toshihiro Sakurai, Megumi Nishimukai, Yuji Takahashi, Atsushi Nagasaka, Shu-Ping Hui, Hiroshi Hara, Hitoshi Chiba
Clinica Chimica Acta, 493, 1, 7, Elsevier BV, 2019年06月
研究論文（学術雑誌）

Apolipoprotein C-II Mimetic Peptide Promotes the Plasma Clearance of Triglyceride-Rich Lipid Emulsion and the Incorporation of Fatty Acids into Peripheral Tissues of Mice
Tomohiro Komatsu, Toshihiro Sakurai, Anna Wolska, Marcelo J. Amar, Akiko Sakurai, Boris L. Vaisman, Denis Sviridov, Stephen Demosky, Milton Pryor, Katsunori Ikewaki, Alan T. Remaley
Journal of Nutrition and Metabolism, 2019, 1, 9, Wiley, 2019年02月03日
研究論文（学術雑誌）, Aim. Plasma apolipoprotein C-II (apoC-II) activates lipoprotein lipase (LPL) and thus lowers plasma triglycerides (TG). We previously reported that a human apoC-II mimetic peptide (C-II-a) decreased plasma TG in apoC-II mutant mice, as well as in apoE-knockout mice. Because it is unknown what tissues take up free fatty acids (FFAs) released from TG after C-II-a peptide administration, we investigated in mice TG plasma clearance and tissue incorporation, using ³H-triolein as a tracer, with and without C-II-a treatment. Methods and Results. Intralipid® fat emulsion was labeled with ³H-triolein and then mixed with or without C-II-a. Addition of the peptide did not alter mean particle size of the lipid emulsion particles (298 nm) but accelerated their plasma clearance. After intravenous injection into C57BL/6N mice, the plasma half-life of the ³H-triolein for control and C-II-a treated emulsions was 18.3 ± 2.2 min and 14.8 ± 0.1 min, respectively. In apoC-II mutant mice, the plasma half-life of ³H-triolein for injected control and C-II-a treated emulsions was 30.1 ± 0.1 min and 14.8 ± 0.1 min, respectively. C57BL/6N and apoC-II mutant mice at 120 minutes after the injection showed increased tissue incorporation of radioactivity in white adipose tissue when C-II-a treated emulsion was used. Higher radiolabeled uptake of lipids from C-II-a treated emulsion was also observed in the skeletal muscle of C57BL/6N mice only. In case of apoC-II mutant mice, decreased uptake of radioactive lipids was observed in the liver and kidney after addition of C-II-a to the lipid emulsion. Conclusions. C-II-a peptide promotes the plasma clearance of TG-rich lipid emulsions in wild type and apoC-II mutant mice and promotes the incorporation of fatty acids from TG in the lipid emulsions into specific peripheral tissues.

Development of a novel fluorescent activity assay for lecithin:cholesterol acyltransferase
Toshihiro Sakurai, Akiko Sakurai, Boris L Vaisman, Takafumi Nishida, Edward B Neufeld, Stephen J Demosky, Maureen L Sampson, Robert D Shamburek, Lita A Freeman, Alan T Remaley
Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, 55, 4, 414, 421, SAGE Publications, 2017年11月02日
研究論文（学術雑誌）, Background

Lecithin:cholesterol acyltransferase (LCAT) is a plasma enzyme that esterifies cholesterol. Recombinant human LCAT (rhLCAT) is now being developed as an enzyme replacement therapy for familial LCAT deficiency and as a possible treatment for acute coronary syndrome. The current ‘gold standard’ assay for LCAT activity involves the use of radioisotopes, thus making it difficult for routine clinical use.

Methods

We have developed a novel and more convenient LCAT activity assay using fluorescence-labelled cholesterol (BODIPY-cholesterol), which is incorporated into proteoliposomes as a substrate instead of radiolabelled cholesterol.

Results

The apparent K_m and V_max were 31.5  µmol/L and 55.8 nmol/h/nmoL, rhLCAT, respectively, for the ³H-cholesterol method and 103.1  µmol/L and 13.4 nmol/h/nmol rhLCAT, respectively, for the BODIPY-cholesterol method. Although the two assays differed in their absolute units of LCAT activity, there was a good correlation between the two test assays ( r = 0.849, P < 1.6 × 10⁻⁷, y = 0.1378x + 1.106). The BODIPY-cholesterol assay had an intra-assay CV of 13.7%, which was superior to the intra-assay CV of 20.8% for the radioisotopic assay. The proteoliposome substrate made with BODIPY-cholesterol was stable to storage for at least 10 months. The reference range ( n = 20) for the fluorescent LCAT activity assay was 4.6–24.1 U/mL/h in healthy subjects.

Conclusions

In summary, a novel fluorescent LCAT activity assay that utilizes BODIPY-cholesterol as a substrate is described that yields comparable results to the radioisotopic method.

Dietary α‐cyclodextrin reduces atherosclerosis and modifies gut flora in apolipoprotein E‐deficient mice
Toshihiro Sakurai, Akiko Sakurai, Ye Chen, Boris L. Vaisman, Marcelo J. Amar, Milton Pryor, Seth G. Thacker, Xue Zhang, Xujing Wang, Yubo Zhang, Jun Zhu, Zhi‐Hong Yang, Lita A. Freeman, Alan T. Remaley
Molecular Nutrition & Food Research, 61, 8, Wiley, 2017年02月24日
研究論文（学術雑誌）, Scope

α‐Cyclodextrin (α‐CD), a cyclic polymer of glucose, has been shown to lower plasma cholesterol in animals and humans; however, its effect on atherosclerosis has not been previously described.

Methods and results

apoE‐knockout mice were fed either low‐fat diet (LFD; 5.2% fat, w/w), or Western high fat diet (21.2% fat) containing either no additions (WD), 1.5% α‐CD (WDA); 1.5% β‐CD (WDB); or 1.5% oligofructose‐enriched inulin (WDI). Although plasma lipids were similar after 11 weeks on the WD vs. WDA diets, aortic atherosclerotic lesions were 65% less in mice on WDA compared to WD (P < 0.05), and similar to mice fed the LFD. No effect on atherosclerosis was observed for the other WD supplemented diets. By RNA‐seq analysis of 16S rRNA, addition of α‐CD to the WD resulted in significantly decreased cecal bacterial counts in genera Clostridium and Turicibacterium, and significantly increased Dehalobacteriaceae. At family level, Comamonadaceae significantly increased and Peptostreptococcaceae showed a negative trend. Several of these bacterial count changes correlated negatively with % atherosclerotic lesion and were associated with increased cecum weight and decreased plasma cholesterol levels.

Conclusion

Addition of α‐CD to the diet of apoE‐knockout mice decreases atherosclerosis and is associated with changes in the gut flora.

Long‐chain monounsaturated fatty acid‐rich fish oil attenuates the development of atherosclerosis in mouse models
Zhi‐Hong Yang, Masahiro Bando, Toshihiro Sakurai, Ye Chen, Beatrice Emma‐Okon, Bree Wilhite, Daiju Fukuda, Boris Vaisman, Milton Pryor, Yoshiyuki Wakabayashi, Maureen Sampson, Zu‐Xi Yu, Akiko Sakurai, Abdalrahman Zarzour, Hiroko Miyahara, Jiro Takeo, Hiroshi Sakaue, Masataka Sata, Alan T. Remaley
Molecular Nutrition & Food Research, 60, 10, 2208, 2218, Wiley, 2016年07月12日
研究論文（学術雑誌）, Scope

Fish oil‐derived long‐chain monounsaturated fatty acids (LCMUFA) containing chain lengths longer than 18 were previously shown to improve cardiovascular disease risk factors in mice. However, it is not known if LCMUFA also exerts anti‐atherogenic effects. The main objective of the present study was to investigate the effect of LCMUFA on the development of atherosclerosis in mouse models.

Methods and results

LDLR‐KO mice were fed Western diet supplemented with 2% (w/w) of either LCMUFA concentrate, olive oil, or not (control) for 12 wk. LCMUFA, but not olive oil, significantly suppressed the development of atherosclerotic lesions and several plasma inflammatory cytokine levels, although there were no major differences in plasma lipids between the three groups. At higher doses 5% (w/w) LCMUFA supplementation was observed to reduce pro‐atherogenic plasma lipoproteins and to also reduce atherosclerosis in ApoE‐KO mice fed a Western diet. RNA sequencing and subsequent qPCR analyses revealed that LCMUFA upregulated PPAR signaling pathways in liver. In cell culture studies, apoB‐depleted plasma from LDLR‐K mice fed LCMUFA showed greater cholesterol efflux from macrophage‐like THP‐1 cells and ABCA1‐overexpressing BHK cells.

Conclusion

Our research showed for the first time that LCMUFA consumption protects against diet‐induced atherosclerosis, possibly by upregulating the PPAR signaling pathway.

Creation of Apolipoprotein C-II (ApoC-II) Mutant Mice and Correction of Their Hypertriglyceridemia with an ApoC-II Mimetic Peptide
Toshihiro Sakurai, Akiko Sakurai, Boris L. Vaisman, Marcelo J. Amar, Chengyu Liu, Scott M. Gordon, Steven K. Drake, Milton Pryor, Maureen L. Sampson, Ling Yang, Lita A. Freeman, Alan T. Remaley
The Journal of Pharmacology and Experimental Therapeutics, 356, 2, 341, 353, Elsevier BV, 2016年02月
研究論文（学術雑誌）

A Novel Apolipoprotein C-II Mimetic Peptide That Activates Lipoprotein Lipase and Decreases Serum Triglycerides in Apolipoprotein E–Knockout Mice
Marcelo J.A. Amar, Toshihiro Sakurai, Akiko Sakurai-Ikuta, Denis Sviridov, Lita Freeman, Lusana Ahsan, Alan T. Remaley
The Journal of Pharmacology and Experimental Therapeutics, 352, 2, 227, 235, Elsevier BV, 2015年02月
研究論文（学術雑誌）

Serum choline plasmalogens—those with oleic acid in sn− 2—are biomarkers for coronary artery disease
Megumi Nishimukai, Ryouta Maeba, Akiko Ikuta, Naoya Asakawa, Kiwamu Kamiya, Shiro Yamada, Takashi Yokota, Mamoru Sakakibara, Hiroyuki Tsutsui, Toshihiro Sakurai, Yuji Takahashi, Shu-Ping Hui, Hitoshi Chiba, Tomoki Okazaki, Hiroshi Hara
Clinica Chimica Acta, 437, 147, 154, Elsevier BV, 2014年11月
研究論文（学術雑誌）

Measurement of single low-density lipoprotein particles by atomic force microscopy
Toshihiro Sakurai, Seiji Takeda, Jun-ya Takahashi, Yuji Takahashi, Norio Wada, Suchin Trirongjitmoah, Takeshi Namita, Shigeki Jin, Akiko Ikuta, Hiroaki Furumaki, Shu-Ping Hui, Hirotoshi Fuda, Masato Fujikawa, Koichi Shimizu, Hitoshi Chiba
Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, 50, 6, 564, 570, SAGE Publications, 2013年07月30日
研究論文（学術雑誌）, Background

The size of lipoprotein particles is relevant to the risk of coronary artery disease (CAD).

Methods

We investigated the feasibility of atomic force microscopy (AFM) for evaluating the size of large low-density lipoprotein (LDL) and small dense LDL (sd-LDL) separated by ultracentrifugation. The measurements by AFM in tapping mode were compared to those by electron microscopy (EM).

Results

There was a significant difference in particle sizes determined by AFM between large LDL (20.6 ± 1.9 nm, mean ± SD) and sd-LDL (16.2 ± 1.4 nm) obtained from six healthy volunteers ( P < 0.05). The particle sizes determined by EM for the same samples were 23.2 ± 1.4 nm for large LDL and 20.4 ± 1.4 nm for sd-LDL. The difference between large LDL and sd-LDL detected by EM was also statistically significant ( P < 0.05). In addition, the particle sizes of each lipoprotein fraction were significantly different between AFM and EM: P < 0.05 for large LDL and P < 0.05 for sd-LDL.

Conclusions

AFM can differentiate between sd-LDL and large LDL particles by their size, and might be useful for evaluating risk for CAD.

Immunological detection of large oxidized lipoproteins in hypertriglyceridemic serum
Toshihiro Sakurai, Norio Wada, Yuji Takahashi, Ayako Ichikawa, Akiko Ikuta, Hiroaki Furumaki, Shu-Ping Hui, Shigeki Jin, Seiji Takeda, Hirotoshi Fuda, Masato Fujikawa, Chikara Shimizu, Hironori Nagasaka, Hiroyuki Furukawa, Seiichi Kobayashi, Hitoshi Chiba
Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, 50, 5, 465, 472, SAGE Publications, 2013年07月15日
研究論文（学術雑誌）, Background

Triglyceride-rich, low-density lipoproteins (TG-rich LDL) have been reported as an oxidized lipoprotein species in patients with severe liver disease. Using TG-rich LDL as an immunogen, we obtained a monoclonal antibody (G11-6) that reacted with TG-rich LDL from patients with liver disease and with metal-oxidized LDL only in the early process of the oxidation reaction. This study determined the G11-6-reactive lipoproteins in hypertriglyceridemic serum.

Methods

Serum samples from healthy volunteers ( n = 12) and hypertriglyceridemic patients ( n = 9) were fractionated by gel filtration and subjected to a sandwich enzyme-linked immunosorbent assay (ELISA) using G11-6 and polyclonal anti-apolipoprotein B antibodies.

Results

Small LDL and larger lipoproteins reacted with G11-6. G11-6-reactive small LDL was identified in both the healthy subjects and hypertriglyceridemic patients, whereas G11-6-reactive larger lipoproteins were found only in the hypertriglyceridemic patients.

Conclusions

G11-6 is a useful tool for detecting increased large oxidized lipoproteins in hypertriglyceridemic patients.

Novel monoclonal antibody recognizing triglyceride-rich oxidized LDLs associated with severe liver disease and small oxidized LDLs in normal subjects
Toshihiro Sakurai, Ayako Ichikawa, Hiroyuki Furukawa, Norio Wada, Atsushi Nagasaka, Yuji Takahashi, Masato Fujikawa, Akiko Ikuta, Hiroaki Furumaki, Maiko Shiga, Chikara Shimizu, Shu-Ping Hui, Shigeki Jin, Seiji Takeda, Hirotoshi Fuda, Hironori Nagasaka, Seiichi Kobayashi, Hitoshi Chiba
Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, 49, 5, 456, 462, SAGE Publications, 2012年07月17日
研究論文（学術雑誌）, Background

Triglyceride-rich low-density lipoproteins (TG-rich LDLs) in the plasma of patients with severe liver disease are reported to change macrophages into foam cells in vitro.

Methods

Male BALB/c mice were immunized with TG-rich LDLs isolated from the plasma of a patient with severe liver disease. The resulting monoclonal antibody (G11-6) was used in a sandwich enzyme-linked immunosorbent assay (ELISA) in combination with polyclonal anti-apolipoprotein B antibodies. The time course of copper-mediated LDL oxidation was monitored using this ELISA. The results were compared with those of the two commercial ELISAs for oxidized LDLs using DLH or ML25, thiobarbituric acid reactive substances and the optical absorbance for the conjugated dienes generated in lipid peroxides. Furthermore, the lipoprotein fractions separated by gel filtration were tested with this ELISA in healthy volunteers ( n = 11) and patients ( n = 3) with liver disease.

Results

G11-6 reacted with oxidized LDLs during only the early phase of copper oxidation, being distinct from the other monoclonal antibodies and methods. G11-6 was confirmed to react with TG-rich LDLs in patients, while it reacted with small LDL particles in normal controls.

Conclusions

The monoclonal antibody G11-6 is useful for detecting oxidized small LDLs in normal controls and oxidized TG-rich LDLs in patients with severe liver disease.

食品由来成分による細胞内酸化脂肪滴形成の抑制効果　　　　　　　　　　　　　　　
柴田ゆず, 櫻井俊宏, 櫻井知子, 佐藤美涼, 惠 淑萍
第31回日本未病学会学術総会, 2024年11月, 口頭発表（一般）

非アルコール性脂肪性肝炎の早期診断のためのLDL中ホスファチジルコリン過酸化物の一斉分析　　　　　　　　　　　　　　　
村上奈々緒, 櫻井俊宏, 山端ありさ, 櫻井知子, 能祖一裕, 藤井佑樹, 千葉仁志, 惠 淑萍
第31回日本未病学会学術総会, 2024年11月, 口頭発表（一般）

Kaempferol-3-O-glucuronideは尿細管細胞HK-2のミトコンドリア膜脂質の改善をもたらす　　　　　　　　　　　　　　　
佐藤紅葉, 櫻井俊宏, 櫻井知子, 惠 淑萍
第58回日本臨床検査医学会北海道支部総会・第34回日本臨床化学会北海道支部例会（合同開催）, 2024年09月, 口頭発表（一般）

質量分析を用いるDilysocardilolipinの測定系の確立　　　　　　　　　　　　　　　
氏家颯花, 櫻井俊宏, 櫻井知子, 千葉仁志, 惠 淑萍
第58回日本臨床検査医学会北海道支部総会・第34回日本臨床化学会北海道支部例会（合同開催）, 2024年09月, 口頭発表（一般）

LDL中ホスファチジルコリン種のアシル鎖の飽和度に着目したNASH患者の特徴　　　　　　　　　　　　　　　
村上奈々緒, 櫻井俊宏, 山端ありさ, 櫻井知子, 能祖一裕, 藤井佑樹, 千葉仁志, 惠 淑萍
第58回日本臨床検査医学会北海道支部総会・第34回日本臨床化学会北海道支部例会（合同開催）, 2024年09月, 口頭発表（一般）

食品由来成分KaempferolのHDLに対する抗酸化作用　　　　　　　　　　　　　　　
櫻井知子, 櫻井俊宏, 益子真明, 佐藤美涼, 惠 淑萍
第58回日本臨床検査医学会北海道支部総会・第34回日本臨床化学会北海道支部例会（合同開催）, 2024年09月, 口頭発表（一般）

ミトコンドリア機能解析が明らかにしたケンフェロールの新機能　　　　　　　　　　　　　　　
櫻井知子, 櫻井俊宏, 何 欣蓉, 千葉仁志, 惠 淑萍
第64回日本臨床化学会年次学術集会, 2024年08月, 口頭発表（一般）

非アルコール性脂肪性肝炎患者におけるLDL中のホスファチジルコリン組成と肝線維化との関連　　　　　　　　　　　　　　　
村上奈々緒, 櫻井俊宏, 山端ありさ, 櫻井知子, 能祖一裕, 藤井佑樹, 千葉仁志, 惠 淑萍
第64回日本臨床化学会年次学術集会, 2024年08月, 口頭発表（一般）

ミトコンドリアの活性化に寄与する化合物の探索：トマチジンの新規機能性　　　　　　　　　　　　　　　
櫻井俊宏, 櫻井知子, 村上奈々緒, 佐藤浩志, 千葉仁志, 惠 淑萍
日本臨床化学会年次学術集会, 2024年08月, 口頭発表（一般）

Effect of kaempferol on improving cardiolipin metabolism in fatty liver and non-fatty liver model cells　　　　　　　　　　　　　　　
Akiko Sakurai, Toshihiro Sakurai, Hsin-Jung Ho, Hitoshi Chiba, Shu-Ping Hui
The 32nd International Congress on Nutrition and Integrative Medicine, 2024年07月, ポスター発表

Development of cell-based assay for screening antioxidants that inhibit oxidized lipid droplet formation　　　　　　　　　　　　　　　
Toshihiro Sakurai, Saki Kamio, Akiko Sakurai, Nanao Murakami, Hitoshi Chiba, Shu-Ping Hui
The 32nd International Congress on Nutrition and Integrative Medicine, 2024年07月, ポスター発表

Enhancement of mitochondrial function with kaempferol, contained as glycoside in Aojiru　　　　　　　　　　　　　　　
Akiko Sakurai, Toshihiro Sakurai, Hsin-Jung Ho, Hitoshi Chiba, Shu-Ping Hui
The Indian Scientists Association in Japan, 2023年11月, ポスター発表

Kaempferol Improves Mitochondrial Respiratory Function in Human Liver-Derived Cell Line　　　　　　　　　　　　　　　
Akiko Sakurai, Toshihiro Sakurai, Hsin-Jung Ho, Hitoshi Chiba, Shu-Ping Hui
The 6th FHS International Conference, 2023年10月, ポスター発表

ケンペロールによるミトコンドリアへの作用　　　　　　　　　　　　　　　
櫻井知子, 櫻井俊宏, 何 欣蓉, 千葉仁志, 惠 淑萍
第63回日本臨床化学会年次学術集会, 2023年10月, 口頭発表（一般）

カルジオリピン代謝に対するβ-カルボリンアルカロイドの効果　　　　　　　　　　　　　　　
櫻井知子, 櫻井俊宏, Dya Fita Dibwe, 住友徹平, 千葉仁志, 惠 淑萍
第62回日本臨床化学会年次学術集会, 2022年09月, 口頭発表（一般）

冠動脈硬化性疾患の病態の把握及び早期診断のための血漿プラズマローゲンの有用性に関しての検討　　　　　　　　　　　　　　　
西向めぐみ, 榊原 守, 横田 卓, 山田史郎, 櫻井俊宏, 高橋祐司, 生田知子, 古牧宏啓, 山木志展, 前場良太, 千葉仁志, 筒井裕之, 原 博
第66回日本栄養・食糧学会, 2012年05月

自製ELISAによる酸化リポ蛋白の測定とその有用性の検討　　　　　　　　　　　　　　　
櫻井俊宏, 生田知子, 古牧宏啓, 高橋祐司, 西端友香, 石川明彦, 古川博之, 和田典夫, 永坂 敦, 惠 淑萍, 神 繁樹, 武田晴治, 布田博敏, 小林清一, 千葉仁志
第58回日本臨床検査医学会年次学術集会, 2011年11月, 口頭発表（一般）

新規測定法による酸化リポ蛋白の解析　　　　　　　　　　　　　　　
櫻井俊宏, 生田知子, 古牧宏啓, 高橋祐司, 西端友香, 石川明彦, 古川博之, 和田典夫, 永坂 敦, 惠 淑萍, 神 繁樹, 武田晴治, 布田博敏, 小林清一, 千葉仁志
第64回日本酸化ストレス学会学術集会, 2011年07月, ポスター発表

apoCIIIとapoEの両者を持つリポ蛋白粒子（Lp-CIII-E）に関する研究　　　　　　　　　　　　　　　
古牧宏啓, 櫻井俊宏, 高橋祐司, 生田知子, 西端友香, 惠 淑萍, 神 繁樹, 布田博敏, 武田晴治, 千葉仁志
第20回日本臨床化学会北海道支部例会, 2010年12月, 口頭発表（一般）

LC-MS/MSによるプラズマローゲンの分子種別リポ蛋白分布の解析　　　　　　　　　　　　　　　
生田知子, 西向めぐみ, 惠 淑萍, 櫻井俊宏, 神 繁樹, 原 博, 千葉仁志
第44回日本臨床検査医学会北海道支部総会, 2010年10月, 口頭発表（一般）

apoCIIIとapoEの両者を持つリポ蛋白粒子（Lp-CIII-E）の分布の検討　　　　　　　　　　　　　　　
古牧宏啓, 櫻井俊宏, 高橋祐司, 生田知子, 西端友香, 惠 淑萍, 神 繁樹, 布田博敏, 武田晴治, 千葉仁志
第50回日本臨床化学会年次学術集会, 2010年09月, 口頭発表（一般）

酸化リポ蛋白の新規測定法の開発　　　　　　　　　　　　　　　
櫻井俊宏, 生田知子, 古牧宏啓, 高橋祐司, 西端友香, 古川博之, 和田典夫, 永坂 敦, 惠 淑萍, 神 繁樹, 武田晴治, 布田博敏, 小林清一, 千葉仁志
第50回日本臨床化学会年次学術集会, 2010年09月, 口頭発表（一般）

リポ蛋白中プラズマローゲンの分布に関する研究　　　　　　　　　　　　　　　
生田知子, 西向めぐみ, 惠 淑萍, 櫻井俊宏, 神 繁樹, 原 博, 千葉仁志
第50回日本臨床化学会年次学術集会, 2010年09月, 口頭発表（一般）

酸化リポ蛋白自己抗体の研究：モノクローナル抗体の作製　　　　　　　　　　　　　　　
西端友香, 櫻井俊宏, 高橋祐司, 古川博之, 和田典夫, 永坂 敦, 惠 淑萍, 生田知子, 古牧宏啓, 神 繁樹, 武田晴治, 布田博敏, 小林清一, 千葉仁志
第57回日本臨床検査医学会学術集会, 2010年09月, 口頭発表（一般）

抗apoE抗体と抗apoCIII抗体のsandwich-ELISAによるレムナントリポ蛋白の検出について　　　　　　　　　　　　　　　
古牧宏啓, 櫻井俊宏, 高橋祐司, 生田知子, 西端友香, 惠 淑萍, 神 繁樹, 布田博敏, 千葉仁志
第57回日本臨床検査医学会学術集会, 2010年09月, 口頭発表（一般）

酸化リポ蛋白自己抗体の研究：臨床的検討　　　　　　　　　　　　　　　
櫻井俊宏, 西端友香, 高橋祐司, 古川博之, 和田典夫, 永坂 敦, 惠 淑萍, 生田知子, 古牧宏啓, 神 繁樹, 武田晴治, 布田博敏, 小林清一, 千葉仁志
第57回日本臨床検査医学会学術集会, 2010年09月, 口頭発表（一般）

LC-MS/MSによるプラズマローゲンのリポ蛋白分布の検討　　　　　　　　　　　　　　　
生田知子, 西向めぐみ, 惠 淑萍, 櫻井俊宏, 神 繁樹, 原 博, 千葉仁志
第57回日本臨床検査医学会学術集会, 2010年09月, 口頭発表（一般）

肝不全患者血中の抗酸化リポ蛋白自己抗体について　　　　　　　　　　　　　　　
櫻井俊宏, 西端友香, 高橋祐司, 古川博之, 和田典夫, 永坂 敦, 惠 淑萍, 生田知子, 古牧宏啓, 神 繁樹, 武田晴治, 布田博敏, 小林清一, 千葉仁志
第6回東日本胆汁酸研究会, 2010年07月, 口頭発表（一般）

酸化リポ蛋白に対する自己抗体の新規測定法の開発　　　　　　　　　　　　　　　
櫻井俊宏, 西端友香, 高橋祐司, 古川博之, 和田典夫, 永坂 敦, 惠 淑萍, 生田知子, 古牧宏啓, 神 繁樹, 武田晴治, 布田博敏, 小林清一, 千葉仁志
第63回日本酸化ストレス学会学術集会, 2010年06月, 口頭発表（一般）

2022年 - 現在
日本臨床化学会